Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.
Type:
Application
Filed:
December 5, 2017
Publication date:
September 26, 2019
Applicants:
Microbiotix, Inc., Albert Einstein College Of Medicine, Inc., The Govermnment Of The United States As Represented By The Secretary Of
The Army
Inventors:
Terry L. Bowlin, Donald T. Moir, Kartik Chandran, John M. Dye, John D. Williams, Zachary D. Aron, Jay P. Barbor, Kelly N. Lively, Peter J. Nash, Debra M. Mills, Arnab Basu